Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin.

Devika Rao,Atrayee Basu Mallick,Titto Augustine,Cecilia Daroqui,Jeeshan Jiffry,Amartej Merla,Imran Chaudhary,Raviraja Seetharam,Arjun Sood,Srikanth Gajavelli,Santiago Aparo,Lakshmi Rajdev,Andreas Kaubisch,Jennifer Chuy,Abdissa Negassa,John M Mariadason,Radhashree Maitra,Sanjay Goel

CANCER RESEARCH（2019）

引用 11|浏览34

暂无评分

摘要

ERCC1 was induced in a sub-population of patients undergoing oxaliplatin treatment, which was associated with poorer outcome, suggesting this could serve as a marker of oxaliplatin response. C/C or C/T genotype in rs11615 locus decreased benefit from oxaliplatin.

查看译文

关键词

ERCC1,FOLFOX,colorectal cancer,oxaliplatin,resistance

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要